Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

ABSTRACT:

SUBMITTER: Kazda CM 

PROVIDER: S-EPMC5439412 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature